Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06918210

Indocyanine Green Fluorescence During Fundus First Laparoscopic Cholecystectomy

Laparoscopic cholecystectomy is the routine method for managing gallstone disease. This is considered a safe procedure with low risk of severe complications. Lesions to the deep bile ducts is, however, a rare complication from laparoscopic cholecystectomy that may have devastating consequences. The risk of bile duct injuries may be reduced by adapting the surgical approach. In general, the operation is started from the lower part of the gallbladder and continued upwards. It may, however, also be initiated from the top of the gallbladder and extended downwards. This approach, also termed fundus first, is routine at a few units.

By injecting Indocyanin Green (ICG) that is excreted into the bile, the bile ducts may be visualized using near infrared light. This is a technique for mapping the anatomical structures adjacent to the gallbladder that has been used in previous studies for preventing bile duct injuries. This method has, however, not been tested at units where fundus first is the routine surgical technique. In the present randomized controlled trial, the investigators intend to evaluate the safety of ICG as a means for reducing the risk of bile duct lesions and to see if it works as intended.

Altogether 294 operations for gallstones will be included in the study. The patients will be randomized to surgery with or without ICG. Regardless of the randomization, all operations will be undertaken with the fundus first technique.

Thirty days after the operation, all data related to the operation are retrieved from the patient records by an assessor that does not know what group the patient was randomized to. The primary endpoint of the study is the time required from the start of the operation until intraoperative cholangiography is done. In addition, total operative time, all surgical complications and need for converting the operation to an open procedure will be recorded.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing laparoscopic cholecystectomy
  • Verbal and written consent provided
  • Age ≥ 18 years

Exclusion criteria

  • Thyroid disease
  • Allergy against ICG or Iodine

Treatment and study plan

Indocyanine Green

Procedure

Visualization of the bile ducts with ICG

Cholangiography

Procedure

Visualization of the bile ducts with intraoperative cholangiography

Primary outcomes

  1. Time to intraoperative cholangiography

    Time frame: During procedure.

    Time from first incision until intraoperative cholangiography

Secondary outcomes

  1. Procedure-related complications

    Time frame: Up to 30 days postoperatively

    Complications related to the cholecystectomy confirmed intraoperatively or postoperatively

  2. Total operative time

    Time frame: During procedure

    Time from first incision to closure of the wounds

  3. Intraoperative gallbladder perforation

    Time frame: During procedure

    Intraoperative iatrogenic gallbladder perforation

  4. Conversion from laparoscopic to open cholecystectomy

    Time frame: During procedure

    Decision to convert from laparoscopic to open cholecystectomy taken intraoperatively

  5. Surgeon perception of complexity

    Time frame: During procedure

    The perception of the complexity of the procedure rated by the surgeon on a numeric rating scale from 0 to 10 where 10 indicates the highest level of complexity

  6. Patient reported outcome

    Time frame: Up to 30 days postoperatively

    Symptoms and satisfaction rated by the patient 30 days postoperatively on a numeric rating scale from 0 to 10 where 10 indicates the highest level of satisfaction and absence of symptoms

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriel Sandblom, Associate Professor

CONTACT

[email protected]

+46704158218

Susanna Haverinen, MD

CONTACT

[email protected]

+46707740080

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Region Västernorrland

Registry information

Acronym: INFUNDUS

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 9, 2025
Registry last updated
Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.